Grants and Contracts Details
The goal of the AHEAD 3-45 Study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment, and determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid PET at 216 weeks of treatment.
|Effective start/end date||1/1/20 → 12/31/23|
- University of Southern California: $1,040,255.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.